IL188317A0 - Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody - Google Patents

Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Info

Publication number
IL188317A0
IL188317A0 IL188317A IL18831707A IL188317A0 IL 188317 A0 IL188317 A0 IL 188317A0 IL 188317 A IL188317 A IL 188317A IL 18831707 A IL18831707 A IL 18831707A IL 188317 A0 IL188317 A0 IL 188317A0
Authority
IL
Israel
Prior art keywords
absence
detection
target antigen
therapeutic antibody
corresponding therapeutic
Prior art date
Application number
IL188317A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL188317A0 publication Critical patent/IL188317A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL188317A 2005-07-06 2007-12-20 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody IL188317A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (1)

Publication Number Publication Date
IL188317A0 true IL188317A0 (en) 2008-04-13

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188317A IL188317A0 (en) 2005-07-06 2007-12-20 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Country Status (19)

Country Link
US (1) US20070009976A1 (https=)
EP (2) EP1902315A1 (https=)
JP (1) JP2008545145A (https=)
KR (1) KR20080016939A (https=)
AR (1) AR053948A1 (https=)
AU (1) AU2006265275A1 (https=)
BR (1) BRPI0612591A2 (https=)
CA (1) CA2613187A1 (https=)
CR (1) CR9635A (https=)
EC (1) ECSP088081A (https=)
IL (1) IL188317A0 (https=)
MA (1) MA29730B1 (https=)
MX (1) MX2008000277A (https=)
MY (1) MY157955A (https=)
NO (1) NO20076662L (https=)
NZ (1) NZ564471A (https=)
RU (1) RU2008103608A (https=)
TW (1) TWI312864B (https=)
WO (1) WO2007003420A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130056201A (ko) * 2000-05-19 2013-05-29 제넨테크, 인크. ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Her2 항체 조성물
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
US8243157B2 (en) 2006-02-07 2012-08-14 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical aberrations
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック, インコーポレイテッド トラスツズマブ−mcc−dm1及びペルツズマブにより早期の乳癌を処置する方法
US11406715B2 (en) 2015-05-30 2022-08-09 Genentech, Inc. Methods of treating HER2-positive metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
US7718387B2 (en) * 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4

Also Published As

Publication number Publication date
EP1902315A1 (en) 2008-03-26
AU2006265275A1 (en) 2007-01-11
TWI312864B (en) 2009-08-01
WO2007003420A1 (en) 2007-01-11
ECSP088081A (es) 2008-02-20
MA29730B1 (fr) 2008-09-01
EP2194380A3 (en) 2010-07-14
CA2613187A1 (en) 2007-01-11
KR20080016939A (ko) 2008-02-22
AR053948A1 (es) 2007-05-23
EP2194380A2 (en) 2010-06-09
CR9635A (es) 2008-02-20
TW200741203A (en) 2007-11-01
NZ564471A (en) 2010-04-30
MY157955A (en) 2016-08-30
US20070009976A1 (en) 2007-01-11
MX2008000277A (es) 2008-03-24
RU2008103608A (ru) 2009-08-20
NO20076662L (no) 2008-04-03
BRPI0612591A2 (pt) 2010-11-23
JP2008545145A (ja) 2008-12-11

Similar Documents

Publication Publication Date Title
IL188317A0 (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
IL178823A0 (en) Platelet biomarkers for the detection of disease
IL227753A0 (en) A qualified antibody or antibody residue
IL189542A0 (en) Proteolysis resistant antibody preparations
IL192604A0 (en) Anti-drug antibody assay
IL235620A0 (en) sp35 antibodies and their uses
SG10201404801YA (en) Monoclonal antibody
SI1964852T1 (sl) Proti-ilt7 protitelo
EP1927962A4 (en) OBSTACLE DETECTION DEVICE
IL185366A0 (en) Antibody
IL179891A0 (en) Tumor specific antibody
BRPI0817637A2 (pt) anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma
DE602005014679D1 (de) Zieldetektionseinrichtung
IL180789A (en) Monoclonal human antibody against human 4 IL
EP1825295A4 (en) REINFORCED DETECTION SYSTEM OF A TARGET
FI20075251A0 (fi) Immunomääritys epästabiilien antigeenien määrittämiseksi
IL185781A0 (en) Antibodies against candida antigens
EP1958341A4 (en) ECHO DETECTION
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
GB0525541D0 (en) Detection of antibodies
EP2184605A4 (en) DUAL RECOGNITION IMMUNOASSAY FOR DETECTION OF ANTIBODIES
EP1938102A4 (en) DETECTION OF AN IMPROVED TARGET LIGAND
ZA200800083B (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
GB0607712D0 (en) Detection assay
GB0412410D0 (en) Protein detection